Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

​ Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...

Read more

LAVA Therapeutics, supported by Ysios Capital, Announces Pricing of Initial Public Offering

by Ysios Capital

LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of i...

Read more

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Read more

Splice Bio, backed by Ysios Capital, Asabys Partners and Caixa Capital Risc, appoints Jean-Philippe Combal as Chairman of the Board of Directors

by Ysios Capital

Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...

Read more

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Read more

Minoryx Therapeutics, participated by Ysios and Caixa Capital Risc, and Sperogenix Therapeutics enter into an exclusive license agreement

by Ysios Capital

Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...

Read more

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...

Read more

VarmX raises €32 million in Series B round led by Ysios Capital and INKEF Capital

by Ysios Capital

The oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...

Read more

La inversión en las startups de las ciencias de la vida y la salud en Cataluña supera por cuarto año consecutivo los 100 millones de euros

by Biocat

El “Estudio de inversión en el sector de las ciencias de la vida y la salud en Cataluña 2020” revela la buena salud del ecosistema, que casi ha igualado durante el primer semestre de 2020 el cap...

Read more

The keys to raise private funding: evaluation of an innovation project

by GENESIS Biomed

Raising private funding is essential for an innovation project to progress and reach market. ITEMAS 2nd webinar of the series about Investment in Covid-19 times tackled the key steps for entrepreneurs...

Read more

Ona Therapeutics raises €30M in Series A financing

by Ysios Capital

Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...

Read more

Ysios Capital presents its third fund of € 200M

by Ysios Capital

Ysios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Los niños amamantados por mujeres inmun...

by Fundació Sant Joan de Déu

Las participantes del estudio son profesionales sanitarias de la organ...

Photos Stream